TCH

[TCH @ecltch]

@badcharts1 @NorthstarCharts Ah thanks yes got in back then ty

[TCH @ecltch]

@NorthstarCharts @badcharts1 Got it wanted to know which post on the website does this chart refer to specifically

[TCH @ecltch]

@NoLimitGains Guide

[TCH @ecltch]

@TheApeOfGoldST @HaroldVeneberg @Ronny26585053 Message sent Thanks

[TCH @ecltch]

@TheApeOfGoldST @Ronny26585053 Ok gotcha thanks for responding Would be interested to hear more when you can Cheers

[Aphex @Windowlicker79]

$PRTG data is coming, it's a great time to invest!

[Matthew Vanis @vanismatthew1]

$PRTG

[TCH @ecltch]

@MylesMcNulty Thanks MM, not ideal but onwards!

[JP @jamvest20]

$PRTG
second solely owned asset about to land in the clinic.
Big milestone to derisk the pipeline

[Just Us @Nightroads]

$PRTG @PortageBiotech’s Adenosine, A2Bs, entering trial any day now. Good KOL to sign up for. Also, new trial on IMM60 and PEM, https://t.co/HeVcfbbiFe Lots finally moving with this one.

[TCH @ecltch]

@feynzz Yes please

[JP @jamvest20]

@GMF782 Timely additions to the presentation ahead of JPM next week.
-highlighting combo date with PEM (Merck collab) this year.

- partnering opportunities and previous high value exits , Biohaven as example.

Chart is looking primed and fundamentals.
Going to be some year

$PRTG

[Just Us @Nightroads]

@IntensityInc $PRTG @PortageBiotech @Merck
Seems newsworthy…https://t.co/r4oeEB8W0E 1/

[Just Us @Nightroads]

Part 3: Notes from an investor. $PRTG @PortageBiotech @Merck @bmsnews @IntensityInc

On Friday $PRTG tweeted info on its adenosine portfolio. If you recall from Part 1 in my thread, @portagebiotech has a pipeline of 14 assets with 7 clinical trials ongoing. The adenosine 1/

[Just Us @Nightroads]

$PRTG @PortageBiotech @Merck @bmsnews So @IntensityInc presented clinical data mid November at SITC titled “Safety and Survival Results From a Phase 1/2 Trial of Intratumoral Agent INT230-6 (cisplatin vinblastine) Induces Immunological Cancer Cell Death Alone or…1/

[Just Us @Nightroads]

instead of getting there with 100 employees and an expensive office in the Massachusetts biotech corridor, we do it with 10 senior people working virtually. If you look at our burn rate, it is substantially lower than the rate you see in other biotech firms.” 6/

[JP @jamvest20]

$PRTG the no1 small bio blockbuster play

Read this interview by Ian Walters, CEO

- new drug development model
- connected ex $BMS board
- multiple clincal assets
- early big pharma engagement

$MRK $BMS $XBI

https://t.co/n3aRWqpa0x